Vertex, CRISPR Therapeutics Land On TIME's Most Influential Companies List - IndiaWest Journal News

Global CRISPR Gene Editing Market Size/Share Worth USD 12.6 Billion by 2034 at a 13.01% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

Austin, TX, USA, July 25, 2025 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled "CRISPR Gene Editing Market Size, Trends and Insights By Product (Kits and Reagents, Services), By Gene Editing Modality (Ex-Vivo Editing, In-Vivo Editing), By Technology (CRISPR/Cas9 Technology, CRISPR/Cas12 Technology, Prime Editing, Epigenetic Editing, Others), By Application (Therapeutic Applications, Agriculture and Livestock…

How Biotech Teams Streamline CRISPR Screening—and Save Time

Introduction: Why CRISPR Screening Still Feels Slow CRISPR-Cas9 technology has revolutionized gene editing, but biotech teams frequently find themselves bogged down by unexpectedly lengthy CRISPR screens. A seemingly straightforward screening process often stretches into months, causing frustration and missed deadlines. Whether you’re a project leader at a startup, an academic PI racing against publication timelines, […]

Vertex, CRISPR Therapeutics Land On TIME's Most Influential Companies List - IndiaWest Journal News

Time India-West News Desk NEW YORK, NY – Two prominent biotechnology companies, Vertex Pharmaceuticals and CRISPR Therapeutics, both led by Indian American CEOs, have been named to TIME’s 2025 list of the 100 Most Influential Companies. The recognition highlights their significant contributions to gene therapy and drug development. Vertex Pharmaceuticals, under the leadership of CEO Reshma Kewalramani, was named in the “Impact Awards” category, …